Welcome to our dedicated page for Exagen news (Ticker: XGN), a resource for investors and traders seeking the latest updates and insights on Exagen stock.
Exagen Inc. (Nasdaq: XGN) is a commercial-stage diagnostics company that describes itself as a leading provider of autoimmune diagnostics and autoimmune testing solutions. Based in San Diego County, California, Exagen focuses on chronic and debilitating autoimmune conditions, particularly autoimmune rheumatic diseases. Its news flow reflects both its operational performance and its scientific and clinical activities in this specialized area.
Company news frequently covers financial results and operational updates, including quarterly earnings releases, preliminary annual results, and related guidance. These updates often discuss revenue trends, test volume for the AVISE CTD panel, average selling price metrics, and cash and cash equivalents, giving investors insight into Exagen’s commercial progress as an autoimmune diagnostics provider.
Exagen’s news also highlights developments in its testing portfolio and research programs. The company reports on enhancements to AVISE CTD, such as the commercial launch of seronegative rheumatoid arthritis markers for anti-PAD4, and on scientific milestones like the acceptance of multiple abstracts at the American College of Rheumatology’s annual meeting. These abstracts address topics including urinary biomarker panels for lupus nephritis, kidney-specific biomarker panels, T cell biomarkers, and multianalyte lupus risk scores.
Additional announcements include participation in healthcare and diagnostics investor conferences and leadership appointments, such as the addition of a Chief Scientific Officer and new board members with experience in life sciences and medical technology. Together, these news items give a view into Exagen’s financial performance, scientific focus, and corporate development. Investors and observers can use the XGN news page to follow how the company reports on its autoimmune testing business, research activities, and strategic initiatives over time.
Exagen Inc. (Nasdaq: XGN), a leading autoimmune testing provider, has announced it will release its second quarter 2024 financial results on August 5, 2024, before the market opens. The company will host a conference call at 8:30 AM ET on the same day, featuring President and CEO John Aballi and CFO Kamal Adawi.
Interested parties can join the call by dialing (201) 389-0918 (U.S.) or (877) 407-0890 (international). A webcast link will be available on Exagen's investor relations website. A replay of the call will be accessible until August 19, 2024, via phone and webcast recording.
Exagen Inc. (Nasdaq: XGN) reported strong first-quarter results for 2024 with total revenue of $14.4 million, a 28.4% increase over the same period last year. The company achieved a gross margin of 59.6%, up from 47.2% in Q1 2023. The AVISE® CTD ASP saw a 35.1% increase to $377. Despite a net loss of $3.4 million, it marked a 56.3% improvement from Q1 2023. Adjusted EBITDA was $(2.0) million, a 67.7% improvement from last year. Cash and cash equivalents stood at $27.3 million with runway into 2026. Exagen raised revenue guidance to at least $55 million and expects adjusted EBITDA to be better than negative $18 million for 2024.
Exagen Inc. (Nasdaq: XGN) has launched a campaign in recognition of Lupus Awareness Month, focusing on enhancing the work done to help those suffering from Systemic Lupus Erythematosus (SLE). The campaign includes partnerships with the Lupus Foundation of America, educational content on social media platforms, and insights into the future of lupus diagnostics and therapies.
Exagen Inc. (Nasdaq: XGN) will announce its financial results for the first quarter of 2024 on May 13, 2024. The company, a leading provider of autoimmune testing, will host a conference call to review the results. Interested parties can access the call via phone or webcast. A replay will be available until May 27, 2024.
FAQ
What is the current stock price of Exagen (XGN)?
What is the market cap of Exagen (XGN)?
